dc.contributor
Institut Català de la Salut
dc.contributor
[George S] Dana-Farber Cancer Institute, Boston, MA, USA. [Blay JY] Centre Léon Bérard, Lyon, France. [Chi P] Memorial Sloan Kettering Cancer Center, New York, NY, USA. Weill Cornell Medicine, New York, NY, USA. [Jones RL] Sarcoma Unit, The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UK. [Serrano C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Somaiah N] The University of Texas MD Anderson Cancer Center, Houston, TX, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Chi, Ping
dc.contributor.author
Somaiah, Neeta
dc.contributor.author
George, Suzanne
dc.contributor.author
Blay, Jean-Yves
dc.contributor.author
Jones, Robin
dc.contributor.author
Serrano, Cesar
dc.date.accessioned
2025-10-25T05:39:35Z
dc.date.available
2025-10-25T05:39:35Z
dc.date.issued
2024-10-25T09:32:34Z
dc.date.issued
2024-10-25T09:32:34Z
dc.identifier
George S, Blay JY, Chi P, Jones RL, Serrano C, Somaiah N, et al. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations. Futur Oncol. 2024;20(27):1973–82.
dc.identifier
https://hdl.handle.net/11351/12128
dc.identifier
10.1080/14796694.2024.2376521
dc.identifier
001306104800001
dc.identifier.uri
http://hdl.handle.net/11351/12128
dc.description.abstract
KIT mutations; Gastrointestinal stromal tumor; Targeted therapy
dc.description.abstract
Mutaciones KIT; Tumor del estroma gastrointestinal; Terapia dirigida
dc.description.abstract
Mutacions KIT; Tumor de l'estroma gastrointestinal; Teràpia dirigida
dc.description.abstract
Somatic KIT activating mutations drive most gastrointestinal stromal tumors (GISTs). Disease progression eventually develops with first-line imatinib, commonly due to KIT secondary mutations, and different kinase inhibitors have various levels of treatment efficacy dependent on specific acquired resistance mutations. Ripretinib is a broad-spectrum switch-control KIT/PDGFRA tyrosine kinase inhibitor for patients with advanced GIST who received prior treatment with three or more kinase inhibitors, including imatinib. Exploratory baseline circulating tumor DNA analysis from the second-line INTRIGUE trial determined that patients with advanced GIST previously treated with imatinib harboring primary KIT exon 11 mutations and secondary resistance mutations restricted to KIT exons 17/18 had greater clinical benefit with ripretinib versus sunitinib. We describe the rationale and design of INSIGHT (NCT05734105), an ongoing Phase III open-label study of ripretinib versus sunitinib in patients with advanced GIST previously treated with imatinib exclusively harboring KIT exon 11 + 17/18 mutations detected by circulating tumor DNA.
dc.description.abstract
This study is sponsored by Deciphera Pharmaceuticals, LLC.
dc.format
application/pdf
dc.publisher
Taylor & Francis
dc.relation
Future Oncology;20(27)
dc.relation
https://doi.org/10.1080/14796694.2024.2376521
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anomalies cromosòmiques
dc.subject
Tracte gastrointestinal - Càncer - Tractament
dc.subject
Proteïnes quinases - Inhibidors - Ús terapèutic
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
dc.subject
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Connective Tissue::Gastrointestinal Stromal Tumors
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
dc.subject
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido conjuntivo::tumores del estroma gastrointestinal
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
